Latest Technology News

Synertec has raised its FY27 revenue guidance by $8.0 million to $8.3 million, pointing to stronger contract conversion and visibility across its Engineering and Powerhouse businesses. The upgrade follows the $45.5 million ANSTO nuclear medicine manufacturing contract, but covers revenue only and not earnings or cash flow.

PMET Resources says Koch Technology Solutions has demonstrated a more selective pathway for turning Shaakichiuwaanaan pollucite concentrate into multiple high-purity caesium chemicals. The result is promising, but the commercial case still depends on larger-scale testing, marketable samples and a planned economic assessment.

Nufarm expects FY26 underlying EBITDA to rise about 25% at the midpoint of its $370 million to $380 million range, while leverage falls from 2.7 times to approximately 2.0 times. The improvement comes alongside a sweeping cost-reduction program, but restructuring charges of up to $110 million post tax remain in the numbers.

Basin Energy has begun preliminary leachability and XRD studies at its Newmans rare earth discovery, with follow-up drilling assays due imminently. The early-stage program adds a recoverability test to a project already showing a 3.3 km mineralised corridor in northwest Queensland.

Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.

Metals Australia has reported a 50 Mt graphite resource, a maiden 21.51 Mt probable ore reserve and strong study-stage economics for its Quebec project. The opportunity is substantial, but the company ended the year with just AUD 3.73 million in cash and no mining revenue.

Plato Global Shares Income Fund delivered a 19.89% net return for the year, beating its global benchmark by 4.94 percentage points, while net assets climbed to A$340.0 million. The fund also launched its ASX-listed PGI2 access product as distributions and investor applications expanded sharply.

AML3D will contribute about A$530,000 to a three-year, A$3.89 million research project aimed at qualifying its Wire-Arc Additive Manufacturing technology for aerospace tooling. The project carries no immediate revenue, but could open the door to future production contracts if qualification succeeds.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

Simble Solutions is extending its NanoSensor technology into terrestrial solar monitoring, using its existing SimbleSense and CarbonView platforms as a potential route to commercialisation. The opportunity remains at the benchmark-testing stage, with space-based solar identified as a longer-term possibility rather than an immediate product or revenue stream.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Nanoveu has received the first packaged engineering samples of its 16nm ECS-DoT edge AI chip from TSMC, moving the program from design files to physical silicon. The next test is whether the added memory, radio and accelerators deliver the power and performance promised on paper.